Pliant Therapeutics Shares Long-Term Data From The INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast Was Well Tolerated At 320 mg With Continued Antifibrotic And Anti-Cholestatic Activity Displayed Across Multiple Measures
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics announced positive 24-week data from its Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC). The 320 mg dose was well tolerated and showed significant improvements in liver stiffness, alkaline phosphatase levels, and hepatocyte function compared to placebo.
July 15, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' Phase 2a trial of bexotegrast in PSC patients showed positive results, with the 320 mg dose being well tolerated and demonstrating significant improvements in liver stiffness, ALP levels, and hepatocyte function compared to placebo.
The positive trial results for bexotegrast, including safety and efficacy in improving liver stiffness and ALP levels, are likely to boost investor confidence in Pliant Therapeutics. This could lead to a short-term increase in PLRX stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100